Viscosupplementation (CPB 0179, reviewed 2026-09-02)
Aetna Clinical Policy Bulletin 0179 covers viscosupplement (hyaluronate) injections for knee osteoarthritis under commercial medical plans, and considers all other indications experimental, investigational, or unproven. Initial approval requires radiographic evidence of knee osteoarthritis or at least five listed signs and symptoms, knee pain that interferes with functional activities, an inadequate response or adverse effects with non-pharmacologic treatment, an inadequate response, intolerance or contraindication to an analgesic trial for at least 3 months, an inadequate response, intolerance or contraindication to intra-articular steroid injections for at least 3 months, and no total knee replacement scheduled within 6 months of starting treatment. Continuation requires improvement in pain and functional capacity after prior injections and at least 6 months since the last injection in the prior completed series. the policy was last reviewed 09/02/2026, and its next review is listed for 01/28/2027.